Get the Stockscreener App
6.13
7.68%
-0.51
Tonix Pharmaceuticals Holding Corp stock is traded at $6.13, with a volume of 1.14M.
It is down -7.68% in the last 24 hours and down -47.74% over the past month.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
See More
Previous Close:
$6.64
Open:
$6.61
24h Volume:
1.14M
Relative Volume:
1.12
Market Cap:
$105.14M
Revenue:
$13.11M
Net Income/Loss:
$-124.02M
P/E Ratio:
-0.4298
EPS:
-14.261
Net Cash Flow:
$-107.25M
1W Performance:
-18.81%
1M Performance:
-47.74%
6M Performance:
-54.08%
1Y Performance:
-69.37%
1-Day Range:
$0.00
$0.00
1-Week Range:
$6.11
$7.72
52-Week Range:
$6.11
$20.69
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
6.13 | 105.14M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-25-26 | Initiated | Raymond James | Strong Buy |
| May-04-26 | Initiated | TD Cowen | Buy |
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals Q3 2026 Earnings Date and Estimates - MarketBeat
Tonix Pharmaceuticals Gains On Update for TNX-102 SL - Baystreet.ca
Tonix Pharmaceuticals Holding (NasdaqGS:TNXP) Stock Forecast & Analyst Predictions - Simply Wall Street
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Raised to "Hold" at Wall Street Zen - MarketBeat
Tonix Pharmaceuticals (TNXP) 10K Form and Latest SEC Filings 2026 - MarketBeat
Why Is Tonix Pharmaceuticals (NASDAQ:TNXP) Moving Into Focus? - Kalkine Media
Tonix Pharmaceuticals Holding (TNXP) Stock Price, News & Analysis - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to Sell - MarketBeat
Tonix Pharmaceuticals (TNXP) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Tonix expands Medicare coverage for fibromyalgia drug TONMYA - Investing.com
Tonix Pharmaceuticals Adds ~21M Medicare Lives for TONMYA, Total Coverage Now ~166M U.S. Lives - TradingView
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA® - Yahoo Finance
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA® - GlobeNewswire
Raymond James reiterates Strong Buy on Tonix Pharma stock at $27 - Investing.com
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - marketbeat.com
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - MarketBeat
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - Yahoo Finance
Could Market Volatility Test Tonix Pharmaceuticals (NASDAQ:TNXP)? - Kalkine Media
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com Canada
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com India
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com UK
Q3 EPS Estimate for Tonix Pharmaceuticals Raised by Analyst - marketbeat.com
What macro factors could move Tonix Pharmaceuticals (NASDAQ:TNXP) shares this week? - Kalkine Media
Tonix Pharma Appoints New Chief Commercial Officer - The Globe and Mail
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer - Minichart
Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer - citybiz
TNXP Looks 393.2% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 - marketscreener.com
Why is Tonix Pharmaceuticals (NASDAQ:TNXP) stock in focus as Wall Street reopens today? - Kalkine Media
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer - Yahoo Finance
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26 - finance.yahoo.com
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference - GlobeNewswire
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference - Yahoo Finance
Tonix CEO will speak at a healthcare conference Sept. 10 - Stock Titan
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com India
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock - MarketBeat
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock - Investing.com
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com UK
Tonix Pharma (NASDAQ: TNXP) CEO adds 2,000 shares in IRA - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Canada
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com UK
Tonix Pharmaceuticals director bagger buys $12,600 in stock - investing.com
Tonix Pharmaceuticals (TNXP) director buys 1,000 company shares - Stock Titan
Tonix (TNXP) Market: Adds 1.29% to Close at $12.55; the Near-Term Reference Band Stretches From $11.92 to $13.18 in the Latest ReadingPositive Gamma - siam.in
Tonix Pharma Names CEO Seth Lederman Interim CMO - The Globe and Mail
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BAGGER RICHARD H | Director |
Aug 20 '26 |
Buy |
12.60 |
1,000 |
12,600 |
1,000 |
| Taylor Carolyn E. | Director |
Jun 12 '26 |
Buy |
10.55 |
1,415 |
14,928 |
1,833 |
| LEDERMAN SETH | Chief Executive Officer |
Jun 09 '26 |
Buy |
11.79 |
5,000 |
58,950 |
9,005 |
| Stillwell Richard Newcomb | Director |
Jun 08 '26 |
Buy |
11.65 |
5,000 |
58,250 |
5,000 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 31 '26 |
Buy |
12.62 |
5,000 |
63,100 |
20,001 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 18 '26 |
Buy |
14.89 |
15,000 |
223,350 |
15,001 |
4.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):